Shares in Eli Lilly were 1% higher in pre-market trading on Wednesday after the pharmaceuticals group beat fourth-quarter results expectations.
Both quarterly earnings and revenue exceeded market forecasts, while US tax changes enabled the company to also raise its guidance for 2018.
Eli Lilly cited the strong performance of its products as well as good cost control.
“Lilly's new products, including Trulicity, Taltz and Jardiance, continued to drive solid revenue growth in the fourth quarter of 2017, while we maintained flat operating expenses," said chief executive David A. Ricks.
The company struck an upbeat tone on the outlook for 2018, highlighting the recent approval of Taltz in the US and EU for active psoriatic arthritis, along with the encouraging signs in the early use of its Verzenio treatment for breast cancer.